Overview

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Eli Lilly and Company
Treatments:
Exenatide
Rosiglitazone